EntreMed Receives Nasdaq Deficie... (ercialize new compounds based on the Com...)

EntreMed Receives Nasdaq Deficiency Notice

Date:4/4/2008

ercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate

Commun
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
2. EntreMed Announces 2008 Corporate and Clinical Program Priorities
3. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
4. EntreMed to Present at BIO CEO and Investor Conference
5. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
6. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
7. EntreMed Appoints Senior Vice President of Research and Development
8. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
9. Memory Pharmaceuticals Receives Nasdaq Notification
10. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
11. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization

Post Your Comments:

EntreMed Receives Nasdaq Deficie...(ercialize new compounds based on the Com...)